Ziopharm Oncology (ZIOP +1.8%) trades higher after intitiating Phase 2 clinical studies of...
Ziopharm Oncology (ZIOP +1.8%) trades higher after intitiating Phase 2 clinical studies of Ad-RTS IL-12 in combination with palifosfamide to treat patients with non-resectable recurrent or metastatic breast cancer.
From other sites
at Nasdaq.com (Mar 25, 2015)
at CNBC.com (Jan 16, 2015)
at Benzinga.com (Jan 15, 2015)
at MarketWatch.com (Jan 14, 2015)
at Nasdaq.com (Jan 14, 2015)
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs